PTC Therapeutics, Inc. NASDAQ:PTCT

Founder-led company

PTC Therapeutics stock price today

$49.11
+3.88
+8.58%
Financial Health
0
1
2
3
4
5
6
7
8
9

PTC Therapeutics stock price monthly change

+35.95%
month

PTC Therapeutics stock price quarterly change

+35.95%
quarter

PTC Therapeutics stock price yearly change

+54.00%
year

PTC Therapeutics key metrics

Market Cap
3.47B
Enterprise value
3.90B
P/E
-6.05
EV/Sales
5.58
EV/EBITDA
-12.55
Price/Sales
4.97
Price/Book
-10.02
PEG ratio
0.83
EPS
-7.68
Revenue
927.55M
EBITDA
-92.65M
Income
-579.22M
Revenue Q/Q
-4.65%
Revenue Y/Y
20.39%
Profit margin
-80%
Oper. margin
-64.03%
Gross margin
93.61%
EBIT margin
-64.03%
EBITDA margin
-9.99%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

PTC Therapeutics stock price history

PTC Therapeutics stock forecast

PTC Therapeutics financial statements

Average Price Target
Last Year

$48

Potential downside: -2.26%

Based on estimate of 3 analysts
  • Analysts Price target

  • Financials & Ratios estimates

PTC Therapeutics, Inc. (NASDAQ:PTCT): Profit margin
Jun 2023 213.80M -198.88M -93.02%
Sep 2023 196.57M -132.97M -67.64%
Dec 2023 307.05M -155.79M -50.74%
Mar 2024 210.11M -91.57M -43.58%
PTC Therapeutics, Inc. (NASDAQ:PTCT): Debt to assets
Jun 2023 1338124000 1.91B 143.29%
Sep 2023 1259885000 1.93B 153.24%
Dec 2023 1903181000 2.72B 143.01%
Mar 2024 1789629000 2.68B 149.95%
PTC Therapeutics, Inc. (NASDAQ:PTCT): Cash Flow
Jun 2023 -14.12M -23.75M 18.46M
Sep 2023 -14.51M -29.59M 3.36M
Dec 2023 -100.28M -94.41M 620.48M
Mar 2024 70.76M -114.93M 540K

PTC Therapeutics alternative data

PTC Therapeutics, Inc. (NASDAQ:PTCT): Employee count
Aug 2023 1,402
Sep 2023 1,402
Oct 2023 1,402
Nov 2023 1,402
Dec 2023 1,402
Jan 2024 1,402
Feb 2024 1,402
Mar 2024 988
Apr 2024 988
May 2024 988
Jun 2024 988
Jul 2024 988

PTC Therapeutics other data

100.00% 0.00%
of PTCT is owned by hedge funds
73.88M -1.43M
shares is hold by hedge funds

PTC Therapeutics, Inc. (NASDAQ:PTCT): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 46191
Apr 2024 0 5981
May 2024 0 20175
Jul 2024 0 2269
Dec 2024 0 209318
Transaction Date Insider Security Shares Price per share Total value Source
Option
BOULDING MARK ELLIOTT officer: EXEC. VP.. Common Stock 7,720 $33.02 $254,914
Option
BOULDING MARK ELLIOTT officer: EXEC. VP.. Common Stock 1,988 $33.02 $65,644
Sale
BOULDING MARK ELLIOTT officer: EXEC. VP.. Common Stock 6,315 $53.14 $335,579
Option
BOULDING MARK ELLIOTT officer: EXEC. VP.. Common Stock 600 $33.02 $19,812
Sale
BOULDING MARK ELLIOTT officer: EXEC. VP.. Common Stock 1,900 $53.13 $100,947
Sale
BOULDING MARK ELLIOTT officer: EXEC. VP.. Common Stock 2,093 $53.74 $112,484
Option
BOULDING MARK ELLIOTT officer: EXEC. VP.. Stock Option (Right to Buy) 7,720 $33.02 $254,914
Option
BOULDING MARK ELLIOTT officer: EXEC. VP.. Stock Option (Right to Buy) 1,988 $33.02 $65,644
Option
BOULDING MARK ELLIOTT officer: EXEC. VP.. Stock Option (Right to Buy) 600 $33.02 $19,812
Option
ALMSTEAD NEIL GREGORY officer: CHIEF TE.. Common Stock 66,956 $51 $3,414,756
Patent
Application
Filling date: 29 Nov 2021 Issue date: 18 Aug 2022
Application
Filling date: 18 Apr 2022 Issue date: 11 Aug 2022
Grant
Filling date: 5 Jun 2018 Issue date: 9 Aug 2022
Grant
Filling date: 27 Jun 2018 Issue date: 26 Jul 2022
Grant
Filling date: 10 Aug 2020 Issue date: 19 Jul 2022
Application
Filling date: 25 Jan 2022 Issue date: 14 Jul 2022
Grant
Filling date: 27 Jun 2018 Issue date: 12 Jul 2022
Application
Filling date: 12 May 2020 Issue date: 30 Jun 2022
Application
Filling date: 9 Mar 2020 Issue date: 16 Jun 2022
Application
Filling date: 10 Apr 2020 Issue date: 9 Jun 2022
Monday, 23 December 2024
prnewswire.com
Thursday, 19 December 2024
prnewswire.com
Tuesday, 17 December 2024
prnewswire.com
Tuesday, 3 December 2024
zacks.com
https://thefly.com
Monday, 2 December 2024
investopedia.com
benzinga.com
investors.com
reuters.com
prnewswire.com
Wednesday, 27 November 2024
benzinga.com
prnewswire.com
Tuesday, 26 November 2024
reuters.com
prnewswire.com
Monday, 25 November 2024
prnewswire.com
Wednesday, 13 November 2024
reuters.com
prnewswire.com
Thursday, 7 November 2024
seekingalpha.com
zacks.com
zacks.com
prnewswire.com
Wednesday, 6 November 2024
zacks.com
Monday, 4 November 2024
prnewswire.com
Wednesday, 30 October 2024
prnewswire.com
Friday, 25 October 2024
prnewswire.com
Thursday, 24 October 2024
prnewswire.com
Friday, 18 October 2024
prnewswire.com
Thursday, 17 October 2024
zacks.com
Monday, 14 October 2024
prnewswire.com
Wednesday, 9 October 2024
zacks.com
  • What's the price of PTC Therapeutics stock today?

    One share of PTC Therapeutics stock can currently be purchased for approximately $49.11.

  • When is PTC Therapeutics's next earnings date?

    Unfortunately, PTC Therapeutics's (PTCT) next earnings date is currently unknown.

  • Does PTC Therapeutics pay dividends?

    No, PTC Therapeutics does not pay dividends.

  • How much money does PTC Therapeutics make?

    PTC Therapeutics has a market capitalization of 3.47B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 34.2% to 937.82M US dollars.

  • What is PTC Therapeutics's stock symbol?

    PTC Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "PTCT".

  • What is PTC Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of PTC Therapeutics?

    Shares of PTC Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are PTC Therapeutics's key executives?

    PTC Therapeutics's management team includes the following people:

    • Dr. Stuart W. Peltz Co-Founder, Chief Executive Officer & Executive Director(age: 65, pay: $1,700,000)
    • Mr. Eric Pauwels Chief Bus. Officer(age: 63, pay: $975,140)
    • Mr. Mark Elliott Boulding Executive Vice President & Chief Legal Officer(age: 64, pay: $804,350)
    • Dr. Neil Almstead Chief Technical Operations Officer(age: 58, pay: $797,410)
    • Ms. Emily Luisa Hill Chief Financial Officer(age: 44, pay: $782,500)
    • Dr. Allan Steven Jacobson Independent Co-Founder, Chairman of Scientific Advisory Board & Director(age: 79, pay: $140,000)
  • Is PTC Therapeutics founder-led company?

    Yes, PTC Therapeutics is a company led by its founders Dr. Stuart W. Peltz and Dr. Allan Steven Jacobson.

  • How many employees does PTC Therapeutics have?

    As Jul 2024, PTC Therapeutics employs 988 workers.

  • When PTC Therapeutics went public?

    PTC Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 20 Jun 2013.

  • What is PTC Therapeutics's official website?

    The official website for PTC Therapeutics is ptcbio.com.

  • Where are PTC Therapeutics's headquarters?

    PTC Therapeutics is headquartered at 100 Corporate Court, South Plainfield, NJ.

  • How can i contact PTC Therapeutics?

    PTC Therapeutics's mailing address is 100 Corporate Court, South Plainfield, NJ and company can be reached via phone at +90 82227000.

  • What is PTC Therapeutics stock forecast & price target?

    Based on 3 Wall Street analysts` predicted price targets for PTC Therapeutics in the last 12 months, the avarage price target is $48. The average price target represents a -2.26% change from the last price of $49.11.

PTC Therapeutics company profile:

PTC Therapeutics, Inc.

ptcbio.com
Exchange:

NASDAQ

Full time employees:

988

Industry:

Biotechnology

Sector:

Healthcare

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

100 Corporate Court
South Plainfield, NJ 07080

CIK: 0001070081
ISIN: US69366J2006
CUSIP: 69366J200